Karyopharm announces updated selinexor data in patients with treatment-naÏve myelofibrosis to be presented at aacr 2023

Newton, mass. , march 14, 2023 /prnewswire/ -- karyopharm therapeutics inc. (nasdaq: kpti), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that results from its phase 1 study evaluating the safety and efficacy of once-weekly selinexor in combination with standard dose ruxolitinib in patients with treatment-naÏve myelofibrosis (nct04562389) have been selected for a poster presentation at the american association for cancer research (aacr) annual meeting 2023, being held april 14-19, 2023 in orlando, florida.
KPTI Ratings Summary
KPTI Quant Ranking